Vildagliptin: a novel oral anti-diabetic drug in the treatment of type 2 diabetes mellitus
10.3760/cma.j.issn.1000-6699.2011.07.000
- VernacularTitle:维格列汀——治疗2型糖尿病的新型口服降糖药
- Author:
Luya ZHANG
;
Qiang LI
- Publication Type:Journal Article
- Keywords:
Vildagliptin;
Dipeptidyl peptidase-4 inhibitor;
Diabetes mellitus,type 2
- From:
Chinese Journal of Endocrinology and Metabolism
2011;27(7):后插1-后插4
- CountryChina
- Language:Chinese
-
Abstract:
Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), which can prevent the cleavage and inactivation of glucagon-like peptide-1 (GLP-1), and thus increases the plasma level of intact GLP-1. Such action promotes the insulin secretion from β cell and suppresses inappropriately glucagon secretion from α cell in a glucose-dependent manner. Vildagliptin used as monotherapy or in combination with other antidiabetic drugs can effectively reduce HbA1C, fasting and postprandial plasma glucose, and improve islet β cell and α cell function in type 2 diabetes mellitus patients with extremely few hypoglycemia and comparable adverse effects with placebo, but no weight gain. The unique drug action, reliable clinical efficacy, and favorable safety and tolerability of vildagliptin make it a novel oral antidiabetic drug for the treatment of type 2 diabetes mellitus.
